Table 4.
Patient discrete choice experiment (DCE) results (n = 306)
| Coef. | Odds ratio | P > z | WtAC PASI90 | WtAC RiskAE | |
|---|---|---|---|---|---|
| PASI 90 (per 10% increase) | 0.1354 | 1.1450 | 0.0000 | − 1.00 | 0.12 |
| Stop rate (per 5% increase) | − 0.0286 | 0.9718 | 0.0000 | 0.42 | − 0.05 |
| Bio-holiday (Yes) | 0.1729 | 1.1888 | 0.0000 | − 12.77 | 1.50 |
| Risk AE (per 1% increase) | − 0.1151 | 0.8913 | 0.0000 | 8.50 | − 1.00 |
| Injection frequency (5 additional) | − 0.1059 | 0.8995 | 0.0000 | 1.56 | − 0.18 |
| Injection type (IV) | − 0.0762 | 0.9266 | 0.0140 | 5.63 | − 0.66 |
| Injection—who (HCP at clinic) | 0.3970 | 1.4874 | 0.0000 | − 29.32 | 3.45 |
AE adverse events, HCP healthcare provider, IV intravenous, PASI 90 90% reduction in the Psoriasis Area and Severity Index score, WtAC PASI90 the percentage changes in PASI90 which would be needed to compensate for the change in the row attribute, WtAC RiskAE the percentage changes in RISK AE would be needed to compensate for the change in the row attribute